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Clostridium difficile is the leading infectious cause of antibiotic-associated diarrhea and colitis. C. difficile infection
(CDI) places a heavy burden on the healthcare system, with nearly half amillion infections yearly and an approximate
20% recurrence risk after successful initial therapy. The high incidence has driven new research on improved
prevention such as the emerging use of probiotics, intestinal microbiome manipulation during antibiotic therapies,
vaccinations, and newer antibiotics that reduce the disruption of the intestinal microbiome. While the treatment
of acute C. difficile is effective in most patients, it can be further optimized by adjuvant therapies that improve the
initial treatment success and decrease the risk of subsequent recurrence. Finally, the high risk of recurrence has
led to multiple emerging therapies that target toxin activity, recovery of the intestinal microbial community, and
elimination of latent C. difficile in the intestine. In summary, CDIs illustrate the complex interaction among host
physiology, microbial community, and pathogen that requires specific therapies to address each of the factors leading
to primary infection and recurrence.
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Introduction
Clostridium difficile infections
Clostridium difficile is a toxigenic, Gram-positive,
spore-forming bacterium that can infect the gas-
trointestinal (GI) tract and cause mucosal dam-
age. People can become infected by C. difficile after
intestinal microbiota disruption through mecha-
nisms such as the usage of antibiotics. Once infected
with C. difficile, clinical manifestations range from
asymptomatic colonization to mild diarrhea and
colitis to severe fulminant colitis and potentially
fatal toxic megacolon. C. difficile causes nearly half
a million infections per year in the United States
alone,1 and costs up to $1.5 billion dollars annually
in attributable healthcare expenses.2
While pseudomembranous colitis was first
described in 1893, it was not known to be associ-
ated with antibiotic usage until 1974.3,4 Even then,
C. difficile was not known to be the causative agent.
C. difficile, first isolated from newborns in 1935,
was not identified as a leading cause of antibiotic-
associated diarrhea and pseudomembranous colitis
until 1978.3,5 At that time,C.difficile infection (CDI)
was seen as a treatable nuisance disease that did
not necessitate specific therapy or the development
of new treatments.6 However, the emergence in the
mid-1990s and early 2000s of CDI epidemics caused
by strains belonging to the type NAP1/BI/027 led to
an increase in incidence and morbidity that galva-
nized the development of new therapeutics, moni-
toring, and testing.7,8
The first step of treatment begins with the correct
identification of the disease. While C. difficile is a
leading cause of antibiotic-associated diarrhea, it is
not the only causative agent. As there are strains
of nontoxigenic C. difficile that are incapable of
causing disease and a high rate of asymptomatic
carriage of toxigenic strains, an accurate diagnosis
cannot depend solely on identifying C. difficile in
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the stool. Instead, diagnosis of C. difficile is depen-
dent on two factors: (1) identification of toxigenic
C. difficile or its toxins or histopathologic or colono-
scopic evidence showing pseudomembranous coli-
tis and (2) signs of clinical disease, such as three
or more unformed stools within 24 h, radiographic
evidence of ileus, or toxic megacolon.9 There are
many tests and algorithms for diagnosing C. diffi-
cile, eachwith strengths andweaknesses. Testing can
include the following as either single tests or as part
of a multistep algorithm: EIA-based toxin A/B tests,
PCR-based nucleic acid amplification tests for tcdB,
or glutamine dehydrogenase tests (whenpairedwith
oneof theprior toxin tests).Thevarious testing algo-
rithms have been summarized in the recent 2018
IDSA/SHEA guidelines.9 The main goal is to iden-
tify only those patients who require treatment and
to classify them in terms of severity potential and
post-therapy recurrence risk. A recurrent case of
CDI is defined as symptom onset and stool speci-
men positive for C. difficile 2–8 weeks following the
last positive specimen during previous treatment of
primary CDI. Such classifications help guide ther-
apy and determine which targeted therapeutics to
use, since emerging CDI therapies are being devel-
oped to specifically address prevention, treatment,
and recurrence reduction.
Current therapies are mainly directed at address-
ing primary CDIs with the use of antibiotics such
as vancomycin, as well as treating recurrent dis-
ease with vancomycin or fidaxomicin. In repeatedly
recurrent disease, additional current approaches
use antibiotic tapers, antibiotic adjuvants, and
fecal microbiota transplants (FMTs).9 Newer ther-
apies are being developed and put into practice
to reduce initial infection; these include probiotics
and vaccines. New treatments can also reduce the
risk of recurrence and severe disease with nar-
row spectrum antibiotics, immunotherapies, and
microbial replacement therapies. In this review, we
will summarize the current therapy recommen-
dations and indicate areas of improvement that
we hope new emerging drugs and treatments will
address.
How the pathogenesis of CDI informs
treatment approaches
The pathogenesis of C. difficile infection repre-
sents the complex interaction among pathogen,
host, and native microbiota (Fig. 1). Spores can
be spread by both asymptomatic carriers and
symptomatic patients, necessitating the isolation of
infected individuals and the appropriate cleaning
of the healthcare environment. The initial phase of
C. difficile infection occurs when spores enter the
gastrointestinal system and local environmental fac-
tors trigger germination and growth of vegetative
cells. Primary bile acids (e.g., taurocholic acid and
cholate) act as germinants during in vitro exper-
iments with glycine as cogerminant.10,11 Native
members of the microbiota have the capacity to
deconjugate and dehydroxylate primary bile acids
into secondary bile acids, some of which have
shown to be inhibitory to vegetative C. difficile.12–14
Antibiotic-mediated alteration of native bacteria in
the microbiota can impair primary bile acid con-
version to secondary bile acids, leading to an envi-
ronment that promotes C. difficile sporulation and
vegetative growth.15
Once C. difficile vegetative cells have grown from
the spores in the colon, they produce the toxins
TcdA,TcdB, andbinary toxin. Specific strainsof tox-
igenicC. difficile produce different levels and subsets
of these toxins. For example, certain strains can pro-
duce TcdA and TcdB but not the binary toxin. TcdA
and TcdB enter the cell by binding to specific cel-
lular receptors found on intestinal epithelial cells.16
After endocytosis, acidification of the endosome
leads to conformational changes of the toxin that
releases the N-terminal glucosyltransferase domain
into the cytoplasm. This domain inactivates specific
enzymes such as the Rho GTPases through glycosy-
lation. This leads to both cytopathic and cytotoxic
downstream effects by altering the cytoskeletal
structure, epithelial permeability, and cell-to-cell
junctions, as well as by activating the inflamma-
some and apoptosis.17,18 With the destruction
of the epithelium, C. difficile infection can cause
diarrhea and lead to complicated cases through
systemic effects such as sepsis, shock, peritonitis,
and bowel perforation as the intestine becomes
compromised.
Targeted antibacterial therapy can be used to
reduce intestinal C. difficile levels. However, even
with successful treatment and clearance, a median
of 21.6% of patients will experience recurrent dis-
ease with an increased risk to reoccur following each
recurrence.19 Thehigh recurrence riskhighlights the
importance of restoring the colonization resistance
against C. difficile.
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Figure 1. Pathogenesis of Clostridium difficile infection and areas for emerging therapy improvement. Starting with normal
microbiota, antibiotic disruption of the intestinal bacterial community results in a susceptible state, which can lead to colonization
with C. difficile. Once germinated, vegetative C. difficile produces a variety of toxins to cause mucosal damage. If the damage
is severe, this may lead to severe disease. With effective antibiotic therapy, C. difficile can be reduced and natural colonization
resistance can develop over time as the natural microbial community recovers. Reinfection or recurrence may occur before this
process is complete. Fecal microbiota transplant may expedite this recovery by directly replacing the missing microbial community
members. Areas marked with a red circle are potential areas where new emerging therapies could improve clinical management.
The interactions among host, pathogen, and
microbiota in CDI present multiple opportunities
for the development of novel therapies that target
specific steps in pathogenesis. For example, emerg-
ing therapies can reduce the risk of CDI by lowering
the effect of systemic antibiotics, decreasing the lev-
els of primary bile acids, increasing secondary bile
acids, and restoring the nativemicrobiota’s ability to
convert primary bile acids to secondary bile acids.
While there is no universally accepted definition
of narrow-spectrum antibiotics, it is accepted in
the field that this refers to antibiotics that affect
a smaller range of bacterial groups, such as those
affecting only Gram-positive bacteria. In contrast,
broad-spectrum antibiotics are those that affect
multiple classes of bacteria, such as those impacting
both Gram-positive and Gram-negative bacteria,
including anaerobic bacteria. It has been shown
that specific broad-spectrum antibiotics may cause
further disruption of the native gut bacteria, leading
to increased risk of recurrence. As such, emerging
therapies targeting the recovery of native bacteria
post-CDI treatment include narrow-spectrum
antibiotics that allow for more rapid recovery
of native bacteria and bacterial replacement
therapies such as specific bacterial communities
delivered by enema or oral ingestion. C. difficile
cells and toxins can also be targeted by preformed
antitoxin and anti-C. difficile antibodies or by
anti-C. difficile antibodies natively produced due to
vaccination. These therapies have the potential to
reduce the risk of CDI, decrease disease severity, and
prevent recurrence by targeting spores, vegetative
cells, and toxins.
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Conventional management of CDI
Initial management after diagnosis
Once a patient is diagnosed with CDI, any inciting
antibiotics should be discontinued if possible.20,21
Initial management may also include decreasing
proton pump inhibitors and antimotility agents,
which have been associated with increased severity
of CDI22 and the subsequent risk for recurrence.23
The next step is to determine the severity of the
illness, as this will guide the therapeutic approach,
with certain treatments recommended based on
severity. In the 2018 IDSA/SHEA guidelines, non-
severe (mild to moderate) disease is defined as diar-
rhea occurring with white blood cell count<15,000
cells/mL and serum creatinine <1.5 mg/dL. Severe
CDI is defined as CDI with white blood cell count
15,000 cells/mL or serum creatinine 1.5mg/dL.
Finally, severe and complicated CDI is defined by
systemic signs of infection and evidence of hypoten-
sion, ileus, or toxic megacolon.9,24
Current management recommendations
C. difficile is resistant to many antibiotics, including
fluoroquinolones andmacrolides, with an increased
resistance to rifampin seen in the 27 strains.25,26
As indicated in the 2018 IDSA/SHEA guidelines,
the treatment of CDI is determined by severity and
recurrence state. For primary CDI, nonsevere dis-
ease is treated by vancomycin (125 mg orally four
times daily for 10 days) or fidaxomicin (200 mg
orally two times daily for 10 days). If neither is
available or tolerated, metronidazole (500mg orally
three times daily for 10 days) can be used instead.9
For severe CDI, the recommendation is vancomycin
(125mg orally four times daily for 10 days) or fidax-
omicin (200mgorally two times daily for 10 days). If
CDI is severe and complicated, vancomycin (500mg
four times daily given orally or by nasogastric tube)
can be given with IV metronidazole (500 mg every
8 h). If ileus is present, vancomycin can be given by
rectal enema in addition to the oral vancomycin and
IV metronidazole. If surgical intervention is neces-
sary, rectal-sparing subtotal colectomy or diverting
loop ileostomy with colonic lavage followed by van-
comycin flushes is recommended. For recurrent dis-
ease, the first recurrence is treated with a standard
course of vancomycin (125 mg orally four times
daily for 10 days) if the previous CDI was treated
with metronidazole. If the previous course was not
metronidazole, the recurrent case is treated with
vancomycin taper (e.g., 125mg orally four times per
day for 10–14 days, two times per day for a week,
1 per day for a week, and finally every 2–3 days
for 2–8 weeks) or fidaxomicin (200 mg orally two
times daily for 10 days). For the second or subse-
quent recurrences, vancomycin taper, vancomycin
(125 mg orally four times daily for 10 days) fol-
lowed by rifaximin chaser (400 mg three times daily
for 20 days), or fidaxomicin therapy (200 mg orally
two times daily for 10 days) can be used. FMT can
be considered for the second or subsequent recur-
rence, but is not recommended for primary CDI or
first recurrence.9 Treatment management and dos-
ing schemes are presented in Figure 2.
In the past, metronidazole was recommended for
mild-to-moderate CDI as a cost-effective treatment,
while vancomycinwas used formetronidazole intol-
erance and/or if the patient has an increased risk
of recurrence. However, recent clinical trials and a
meta-analysis have shown that vancomycin is supe-
rior to metronidazole for nonsevere CDI, with a
percentage resolution of 87% compared with 78%
for metronidazole. The 2018 IDSA/SHEA guide-
lines indicate the use of vancomycin or fidaxomicin
for nonsevere CDI, with metronidazole reserved for
cases when the other two drugs are not available or
tolerated.9
Fidaxomicin is a narrow-spectrum, nonab-
sorbable macrocyclic antibiotic that inhibits the
bacterial RNA polymerase  subunit (rpoB) and
has been found to be noninferior to vancomycin
in success rate in multiple phase III trials, but
shows substantially reduced rate of recurrence.27
Fidaxomicin has bactericidal activity against
C. difficile by inhibiting RNA polymerase and dis-
rupting RNA synthesis.28 The narrow-spectrum
activity of fidaxomicin potentiallymaintains the sta-
bility of the intestinal microbiota at a higher level,
leading to amore transient loss of colonization resis-
tance and more robust recovery of the microbiota
after treatment. Fidaxomicin shows similar clini-
cal cure rates with reduced recurrence rates.9,29–31
While fidaxomicin is more costly than vancomycin,
the treatmentmay lower the overall cost by reducing
recurrence rates if used to treat patients with a high
recurrence risk.29,32
Additionally, studies have been done on using
alternative fidaxomicin dosing regimens for treat-
ing primary and recurrent CDI by looking at clinical
cure rate and recurrence reduction. Soriano et al.33
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Figure 2. Current clinical management guidelines for C. difficile infection (CDI). This diagram reviews the recommended
treatment approaches for primary and recurrent CDI, depending on disease severity based on the 2018 IDSA/SHEA guidelines.
Additionally, there is someevidence forfidaxomicin inplaceof rifaximinasa chaser for recurrentCDIand theEXTENDtrialdid show
evidence for using extended-pulsed fidaxomicin for primary CDI; however, this is not currently reflected in the guidelines.9,33,34,37
*Primary CDI is defined as a new episode of symptoms with no previous positive C. difficile test result within 8 weeks and
confirmation of CDI by diagnostic testing.
showed in a case study of patients with multiple
recurrent CDI that only 2 out of 11 patients (18%)
had recurrence when given fidaxomicin in a taper-
ing dose regimen as compared with 3 of 8 patients
(38%) who were given only fidaxomicin as a chaser
twice daily for 10 days. These patients received
these chasing or tapering regimens after a standard
CDI antibiotic therapy. This study indicated that
fidaxomicin chasers and tapered regimens could
help prevent recurrence in patients experiencing
multiple recurrent CDI. However, the study was
not randomized and had a low sample size,
requiring future studies to further evaluate these
findings.
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Figure 3. Yearly incidence of the U.S. inpatient CDI per 100,000 hospitalizations and the number of first-submission clinical trials
by year. The submission of clinical trials increased following the increase in yearly incidence of CDI in the United States. Data on
incidence were obtained from HCUPnet and clinical trial data were obtained from ClinicalTrials.gov. Only trials with C. difficile in
the condition category were included.41,42
EXTEND, a recent randomized, controlled, phase
IIIb/IV trial, compared the effects of extended-
pulsed fidaxomicin treatment (200 mg orally given
twice daily for days 1–5, once daily every other
day from days 7 to 25) with vancomycin treat-
ment (125 mg orally four times a day for 10 days)
for primary and recurrent CDI. Of the patients
receiving the extended-pulsed fidaxomicin treat-
ment, 124 of 177 (70%) achieved a sustained clinical
cure at 30 days after treatment, while in compari-
son only 106 of 179 (59%) patients receiving the
vancomycin treatment achieved a sustained clinical
cure at 30 days after treatment (P = 0.030, odds
ratio 1.62 [95% CI: 1.04–2.54]). Additionally, the
extended-pulsed fidaxomicin treatment resulted in
a lower recurrence at 90 days (6%) compared with
the vancomycin treatment (19%) (P = 0.00073,
odds ratio 0.29 [95% CI: 0.14–0.60]). This study
showed that the extended-pulsed fidaxomicin treat-
ment resulted in a higher rate of clinical cure for
the patients as a whole, with reduced recurrence.34
However, this studywasnot powered to lookdirectly
at this treatment for patients starting with recur-
rent CDI, and the study also showed that extended-
pulsed fidaxomicin treatment may be inferior for
severe CDI. Finally, the study did not compare
standard fidaxomicin therapy or extended-pulsed
vancomycin therapy to the extended-pulsed fidax-
omicin. Future study is needed to look at the
effectiveness of this treatment for multiple recur-
rent CDI and to compare its effectiveness to stan-
dard fidaxomicin and extended-pulsed vancomycin
therapy.
Finally, rifaximin is a nonabsorbable rifamycin
formula that acts to inhibit bacterial RNA synthe-
sis by binding to bacterial DNA-dependent RNA
polymerase. Although rifaximin has a broad spec-
trum of activity, it appears to only minimally
disrupt the intestinal microbiota and has high activ-
ity against C. difficile,35 but resistance may develop
rapidly. Rifaximin has shown potential as an adju-
vant to conventional therapy for recurrent disease
as a chaser, with one study finding that patients who
received rifaximin after conventional therapy expe-
rienced recurrence at 15%, and those who received
a placebo after conventional therapy experienced a
21% recurrence rate.36,37 A small retrospective study
of 32 patients treated with rifaximin for recurrent
C. difficile infections found the treatment to be safe
and with no recurrence of CDI after 12 weeks in
17 patients (53%).38 As such, rifaximin is not used
for primary therapy, but can be used as a chaser to
vancomycin to reduce recurrent diarrhea.9,37,39
Areas for improvement and targets for
emerging therapies
While current therapies lead to successful treatment
of mild-to-moderate disease, there are improve-
ments needed. CDI therapy success requires the
resolution of diarrhea with absence of severe
abdominal discomfort for more than two consec-
utive days. Although successful treatment rates are
high, as many as 18.9–27.3% of patients do not
respond to treatment and experience treatment
failure.40 Additionally, the high severity disease and
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Figure 4. CDI emerging therapies targeted at prevention, primary therapy, or recurrence prevention and management. Clinical
trial datawere obtained fromClinicalTrails.gov.Only clinical trials listed onClinicalTrials.govwere included. Ifmultiple therapeutic
aims are being studied for a given drug, we sorted it by the categorization used in this article for the discussion section. Refer to
Tables 1–3 for specifics on each therapeutic.41
the significant rate of recurrence are promising tar-
gets for emerging therapies.
The U.S. National Library of Medicine’s records
of clinical trials pertaining to C. difficile infec-
tions show a sharp increase in the number of clin-
ical trials since the early 2000s that follows the
increase in yearly incidence of inpatient CDI per
100,000 hospitalizations observed from HCUPnet
data (Fig. 3).41,42 This highlights the importance of
developing new therapies to address the increase
in incidence of CDI. While a large portion of
the clinical trials are studying topics ranging from
optimizing current antibiotic protocols and dos-
ing and FMT, many trials are studying emerging
therapies that target prevention, primary therapy,
and/or reducing and treating recurrence (Fig. 4).
These emerging therapeutics are discussed below
and are organized by which phase of pathogen-
esis they target: prevention, primary therapy, or
recurrence (Fig. 1).
Prevention of CDI
The high incidence of CDI necessitates the devel-
opment of strategies aimed at reducing intestinal
microbial changes caused by systemic antibiotics,
restoring colonization resistance and native bacte-
rial communities, as well as reducing sporulation,
colonization, and toxin production by C. difficile.
The current emerging therapies are: -lactamases
targeted at reducing systemic -lactam antibiotic
disruption of intestinal bacteria; oral probiotics and
bacterial replacement to restore bacteria associated
with colonization resistance; vaccination to pro-
duce anti-C. difficile antibodies targeting spores,
vegetative cells, and toxins; and therapies targeting
toxin damage and CDI development once colonized
(Table 1).
-Lactamase. -Lactam antibiotics are associ-
ated with an increased risk for subsequent CDI.
By reducing the amount of active -lactam
antibiotic reaching the intestinal bacteria while
preserving systemic drug activity, nonabsorbable
-lactamases potentially prevent the loss of natural
colonization resistance (Fig. 5). SYN-004 (ribaxa-
mase) is a recombinant -lactamase manufactured
by Synthetic Biologics that is derived from P1A, a
-lactamase isolated from Bacillus licheniformi, and
it is formulated for oral dosing that aims to reduce
the effects on intestinal microbiota of -lactam
antibiotics that are given systemically. Preclinical tri-
als in dogs showed that SYN-004 was well tolerated,
minimally absorbed, and had no measurable effects
on the systemic levels of coadministered intra-
venous ceftriaxone.43 These results supported the
progression of SYN-004 to clinical trials. Animal
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Table 1. Emerging therapies targeted at prevention of CDI
Type
Treatment
name Admin.
Current or last
phase
completed Mechanism Prevention
Primary
therapy
Recurrence
prevention/
treatment
-Lactamase SYN-004 Oral Phase II
ongoing
A recombinant
-lactamase from
Bacillus licheniformi
that acts to reduce the
effect of systemic
-lactam antibiotics on
the intestinal
microbiota.
X
Microbial Bio-K Oral Phase III
ongoing
Probiotic containing three
bacterial species:
Lactobacillus
acidophilus (CL1285),
Lactobacillus casei
(LBC80R), and
Lactobacillus rhamnosus
(CLR2).
X X
Microbial VSL3 Oral Phase II/III
completed
A refrigerated probiotic
consisting of eight
different live strains of
bacteria:
Bifidobacterium breve,
Bifidobacterium
longum,
Bifidobacterium
infantis,
Lactobacillus
acidophilus,
Lactobacillus
plantarum,
Lactobacillus paracasei,
Lactobacillus delbrueckii
subsp. bulgaricus, and
Streptococcus
thermophile.
X
Microbial HOWARU
Restore
Oral Phase I
complete
Probiotic containing four
strains: Lactobacillus
acidophilus,
Bifidobacterium lactis
Bl-04,
Bifidobacterium lactis
Bi-07, and Lactobacillus
paracasei Lpc-37.
X
Toxin vaccine VLA84 IM Phase II
completed
A recombinant vaccine
composed of truncated
portions of C. difficile
toxins A and B. Given
IM, this vaccine may
induce antitoxin
antibody production.
X
Continued
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Table 1. Continued
Type
Treatment
name Admin.
Current or last
phase
completed Mechanism Prevention
Primary
therapy
Recurrence
prevention/
treatment
Toxin vaccine ACAM-
CDIFF
IM Phase III dis-
continued
Toxin vaccine of
C. difficile toxins A and
B. Given IM, this
vaccine may induce
antitoxin antibody
production.
X X
Toxin vaccine PF-
06425090
IM Phase II and
III ongoing
Genetically modified toxin
vaccine of
C. difficile toxins A and
B. Given IM, this
vaccine may induce
antitoxin antibody
production.
X
Oral vaccine CDVAX Oral Phase I
terminated
An oral vaccine against
C. difficile that utilizes
spores from a genetically
modified bacterium to
produce an oral vaccine
that may induce strong
mucosal immunity.
X
Lactoferrin Lactoferrin Oral Phase II
ongoing
May have the potential to
reduce the cytotoxic
damage of C. difficile
toxin B and may delay
C. difficile growth and
reduce toxin
production.
X
Note: For each emerging therapy, the administration route, current or last phase completed, and mechanism are listed. Additionally,
each drug is marked for the applications it is being studied for in clinical trials, namely, prevention, primary therapy, or recurrence
prevention/treatment. Clinical trial information was obtained from ClinicalTrials.gov.41
studies further showed that SYN-004 was capable
of degrading ceftriaxone in the GI tract of dogs and
reduced microbial changes in the gut of pigs treated
with ceftriaxone.44 Twophase I clinical trials showed
that SYN-004waswell tolerated and remained local-
ized to the intestines.45 Two phase II clinical tri-
als confirmed that SYN-004 is capable of degrading
systemically administered -lactam antibiotics that
enter the intestines.46 A recently completed phase
II clinical trial studied the ability of SYN-004 given
orally in a 150 mg dose to prevent CDI in patients
with a lower respiratory tract infection receiving IV
ceftriaxone (NCT02563106). Results have not yet
been posted. One limitation for -lactamase treat-
ment is that it will only be useful for patients receiv-
ing systemic -lactam antibiotics. Non--lactam
antibiotics that have a high risk for CDI, such as
quinolones and clindamycin, would not be affected
by a -lactamase.
Probiotics. Probiotics are “live microorganisms
that, when administered in adequate amounts, con-
fer a health benefit on the host.”47 The aim of pro-
biotics when used for CDI prevention is to restore
bacteria associated with colonization resistance that
may have been disrupted by systemic antibiotic
usage (Fig. 5). While probiotics have the potential
to prevent CDI, more research is needed to deter-
mine which patients would benefit from probiotic
treatment and what the long-term side effects of
probiotic administration are.48
Bio-K is a probiotic manufactured by Bio-K
Plus R© International containing three bacterial
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Table 2. Emerging therapies targeted at primary management of CDI
Type Treatment name Admin.
Current or
last phase
completed Mechanism Prevention
Primary
therapy
Recurrence
prevention/
treatment
Antibiotic Cadazolid Oral Phase III
completed
Inhibits protein
synthesis and to some
extent inhibits DNA
synthesis. Inhibits
sporulation, toxin
production, and is
also bactericidal.
X
Antibiotic CRS3123 Oral Phase I
completed
Narrow-spectrum
antibiotic that acts by
inhibiting bacterial
methionyl-tRNA
synthetase, with high
activity against
Gram-positive
bacteria and
C. difficile but low
activity against
Gram-negative
bacteria.
X
Antibiotic LFF571 Oral Phase II
completed
Semisynthetic
thiopeptide that acts
on Gram-positive
bacteria by blocking
protein synthesis.
X
Antibiotic MCB3837/MCB3681 IV Phase I
completed
Hybrid
fluoroquinolone-
oxazolidinone that
has a water-soluble
prodrug formulation
termed MCB3837
which can be given by
IV.
X
Antibiotic Nitazoxanide Oral Phase III
completed
Noncompetitive
inhibitor of the
pyruvate-
ferredoxin/flavodoxin
oxidoreductases with
anti-C. difficile
activity.
X
Antibiotic Ramoplanin Oral Phase III,
Phase IIb
ongoing
Ramoplanin is a
glycolipodepsipeptide
which disrupts cell
wall biosynthesis by
binding to
peptidoglycan. It is
nonabsorbable, binds
to spores, and kills
vegetative C. difficile
cells in vitro.
X
Continued
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Table 2. Continued
Type Treatment name Admin.
Current or last
phase
completed Mechanism Prevention
Primary
therapy
Recurrence
prevention/
treatment
Antibiotic Ridinilazole Oral Phase II
completed
Narrow-spectrum,
nonabsorbable novel
antibiotic that
potentially impacts
cell division, but the
mechanism is not
fully understood.
X
Antibiotic Surotomycin Oral Phase III
completed
Bactericidal cyclic
lipopeptide that acts
to dissipate the
membrane potential
of C. difficile.
X
Antibiotic Tigecycline IV Interventional
completed
A glycylcyline which
acts by binding to the
30S ribosomal
subunit and
inhibiting protein
translation by
blocking tRNA
molecules from
entering the A site of
the ribosome.
X
Binder CASAD Oral Phase II trial
terminated
Sequesters C. difficile
toxins A and B with
limited off-target
protein binding.
X
Binder GT267-004 Oral Phase III
completed
A polystyrene binder
that may sequester
C. difficile toxins
A and B.
X
Binder GT160-246 Oral Phase II
completed
A high molecular
weight soluble
anionic polymer that
has been shown in
hamsters to reduce
mortality from
C. difficile infections
and in vitro data
suggest that it can
neutralize the activity
of toxins A and B.
X
Alanyl-glutamine Alanyl-glutamine Oral Phase II
terminated
A dipeptide that has
been shown to have
potential therapeutic
effects in reducing
C. difficile toxin
damage in intestinal
epithelial cells.
X
Continued
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Table 2. Continued
Type Treatment name Admin.
Current or
last phase
completed Mechanism Prevention
Primary
therapy
Recurrence
prevention/
treatment
Antibody IVIG IV Phase IV
termi-
nated
Intravenous
immunoglobulins
derived from pooled
human serum.
X
Antibody SBI Oral Active Serum-derived bovine
immunoglobulins.
X
Polyclonal antibody IMM-529 Oral Phase I/II
trial
ongoing
Polyclonal antibodies
against TcdB,
vegetative cells, and
spores.
X
Bowel prep NuLYTELY Oral Phase IV
recruit-
ing
A formulation of the
osmotic laxative PEG
3350 and electrolytes
that can be used to
reduce the luminal
load of C. difficile
spores and toxins.
X
Note: For each emerging therapy, the administration route, current or last phase completed, and mechanism are listed. Additionally,
each drug is marked for the applications it is being studied for in clinical trials, namely, prevention, primary therapy, or recurrence
prevention/treatment. Clinical trial information was obtained from ClinicalTrials.gov.41
species: Lactobacillus acidophilus (CL1285), Lacto-
bacillus casei (LBC80R), and Lactobacillus rham-
nosus (CLR2). After an outbreak in the 284-bed
community hospital Pierre-Le Gardeur in Quebec,
every inpatient on antibiotics was prophylactically
given Bio-K within 12 h of the antibiotic prescrip-
tion. For 10 years, 44,835 inpatients were observed,
and it was found that rates of CDI dropped from 18
cases per 10,000 patient-days to 2.3 cases per 10,000
patient-days. The rates for C. difficile infections
at this hospital were found to be lower than
comparable Canadian hospitals. No lactobacillus
bacteremia was observed and it was concluded that
Bio-K was safe and efficacious.49 In a completed
phase III trial, Bio-K prophylaxis after antibiotic
usage reduced antibiotic-associated diarrhea and
C. difficile–associated diarrhea. Patients either
received two capsules per day (Pro-2) or one cap-
sule per day (Pro-1). Patients received the probiotics
within 36 h of antibiotic initiation and continued to
receive the probiotics 5 days after antibiotics were
concluded. Patients were followed up to 21 days
after discontinuationof the probiotic. The incidence
rates for antibiotic-associated diarrhea for Pro-2,
Pro-1, and placebo were 15.5%, 28.2%, and 44.1%,
respectively. Rates of C. difficile–associated diarrhea
for Pro-2, Pro-1, and placebo were 1.2%, 9.4%,
and 23.8%, respectively. Additionally, the duration
of antibiotic-associated diarrhea was reduced
(2.8 days for Pro-2, 4.1 days for Pro-1, and 6.4 days
for placebo).50 These results indicate that Bio-K and
similar probiotics could be efficacious for the pre-
vention of CDI subsequent to antibiotic exposure.
VSL#3 R© (VSL3) is a refrigerated probiotic man-
ufactured by Alfasigma that consists of eight
different live strains of bacteria, including: Bifi-
dobacterium breve, Bifidobacterium longum, Bifi-
dobacterium infantis, L. acidophilus, Lactobacillus
plantarum, Lactobacillus paracasei, Lactobacillus-
delbrueckii subsp. bulgaricus, and Streptococcus
thermophiles.51 VSL#3 was shown in a phase
II/III trial (NCT00973908) to reduce the rate of
antibiotic-associated diarrhea when given as a pro-
phylaxis to average-risk hospitalized patients (0%
for VSL#3 versus 11.4% for placebo). In this study,
the VSL#3 patients received a VSL#3 sachet twice
a day for the duration of their antibiotic course
and 1 week after, while the placebo group received
a placebo sachet twice daily instead. The study
did not observe any cases of C. difficile–associated
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Table 3. Emerging therapies targeted at recurrent CDI prevention and management
Type Treatment name Admin.
Current or last
phase
completed Mechanism Prevention
Primary
therapy
Recurrence
prevention/
treatment
Antitoxin anti-
body
Bezlotoxumab/
actoxumab
IV Phase III
ongoing
Human monoclonal
antibodies against TcdA
(actoxumab) and TcdB
(bezlotoxumab) that can
prevent toxin damage at
the intestinal barrier.
X
Oral bovine
antibodies
Colostrum Oral Phase II/III
withdrawn
Colostrum from
C. difficile–immunized
cows.
X X
Oral bovine
antibodies
MucoMilk Oral Phase II/III
terminated
A whey protein concentrate
40% (WPC-40) enriched
with polyclonal antibodies
that is produced from the
milk of cows immunized
with formaldehyde-
inactivated C. difficile cells
and C. difficile toxin filtrate.
X
Microbial SER-109 Oral Phase III
ongoing
A capsule consisting of
bacterial spores derived
from screened human
donor stool.
X
Microbial SER-262 Oral Phase I
ongoing
A manufactured microbial
therapeutic.
X
Microbial CBM588 Oral Phase II
withdrawn
A probiotic consisting of
Clostridium butyricum,
which lacks toxins
associated with C. difficile
infections.
X
Microbial MET-2 Oral Phase I
recruiting
Consists of a live microbe
community derived from
healthy donor stools.
X
Microbial RBX2660 Enema Two Phase II
and one
Phase III
ongoing
A stool-derived standardized
therapy consisting of live
bacteria suspension.
Suspension is given by
retention enema and is
derived from healthy
donors.
X
Microbial RBX7455 Oral Phase I
ongoing
A lyophilized oral
formulation of RBX2660,
which is stable at room
temperature.
X
Microbial CP101 Oral Phase II
ongoing
Encapsulated lyophilized fecal
microbiota derived from
human donors.
X
Nontoxigenic
Clostridium
difficile
VP20621 Oral Phase II
ongoing
Consists of spores from the
nontoxigenic C. difficile
(NTCD) strain M3.
X
Continued
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Table 3. Continued
Type
Treatment
name Admin.
Current or last
phase
completed Mechanism Prevention
Primary
therapy
Recurrence
prevention/
treatment
Secondary bile
acid
Ursodiol Oral Phase IV
recruiting
Urodeoxycholic acid is being
used as a surrogate for
deoxycholic acid, a
secondary bile acid.
Secondary bile acids have
been shown to suppress
C. difficile growth in vitro.
X
Note: For each emerging therapy, the administration route, current or last phase completed, and mechanism are listed. Additionally,
each drug is marked for the applications it is being studied for in clinical trials, namely, prevention, primary therapy, or recurrence
prevention/treatment. Clinical trial information was obtained from ClinicalTrials.gov.41
diarrhea in either the VSL#3 or placebo groups.51
In this study, adverse event rates were found to be
similar between the VSL#3 and placebo groups.
Further studies are needed to determine which
populations of patients would benefit from this pro-
phylactic therapy and to study the ability of VSL#3
to prevent CDIs in high-risk patients. VSL#3 could
also be tested for its ability to reduce recurrence.
HOWARU R© Restore is a four-strain probiotic
manufactured by DuPontTM consisting of L. aci-
dophilus,Bifidobacterium lactisBl-04,B. lactisBi-07,
and L. paracasei Lpc-37.52 In a randomized dose–
response study, patients treated with antibiotics
were given either high-doseHOWARURestore, low-
doseHOWARURestore, or placebo as a preventative
measure. Antibiotic-associated diarrhea was lower
in the probiotic groups, with rates of 12.5%, 19.6%,
and 24.6% for the high dose consisting of 1.70 ×
1010 colony-forming units (CFUs), the low dose
consisting of 4.17 × 109 CFUs, and the placebo,
respectively. Both probiotic groups had reduced
levels of C. difficile–associated diarrhea, with rates
of 1.8% in the probiotic groups and 4.8% in the
placebo groups.53 No adverse events were found to
be related to HOWARU Restore, with the adverse
event rate being 4.2%, 4.2%, and 7.2% in the high
dose, low dose, and placebo groups, respectively. An
earlyphase I trial (NCT02207140)was recently com-
pleted with results pending that studied the effects
of HOWARU Restore on healthy elderly patients
and the resulting levels of C. difficile and changes in
microbial diversity in fecal samples.
Additional clinical trials have been or are being
performed looking specifically at the ability of Lac-
tobacillus reuteri probiotics in the prevention of
antibiotic-associated diarrhea or C. difficile infec-
tion. A phase III trial was recently completed
and another clinical trial is currently recruiting
(NCT01295918, NCT02127814). In the completed
phase III trial, patients in the treatment arm were
given a chewable tablet containing 1 × 108 CFUs of
L. reuteri (produced by BioGaia R© AB) once per day
during their antibiotic treatment and then contin-
ued for 7 days after their antibiotic treatment was
concluded. Results have not yet been posted.
Vaccines. Asymptomatic carriage of C. difficile is
associated with a decreased risk of developing CDI.
Additionally, a patient’s levels of antibodies against
C. difficile toxins correlates inversely with the devel-
opment of recurrent disease.54,55 As such, the devel-
opment of vaccinations against C. difficile and its
toxins has the potential to prevent not only the ini-
tial disease but recurrence as well (Fig. 5). Vaccines
have similar advantages and limitations to probi-
otics. As they are preventative in nature, it is impor-
tant to determinewhichpatientswould benefit from
vaccination.
VLA84 (IC84) is a recombinant vaccine devel-
oped by ValnevaTM that is composed of truncated
portions of C. difficile toxins A and B. In a phase I
trial of 51 adult and 50 elderly patients, VLA84 was
well tolerated and induced high levels of antibodies
against C. difficile toxins A and B.56 A phase II trial
(NCT02316470) was completed in 2015, in which
patients were divided into four groups receiving
either VLA84 75 g without Alum (150 patients),
VLA84 200g without Alum (150 patients), VLA84
200 g with Alum (150 patients), or placebo (50
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Figure 5. Emerging therapy therapeutic targets for management of CDI—prevention, primary treatment, and recurrence reduc-
tion. Boxes indicate therapies, while arrows indicate the effect of the therapies. Black arrows indicate events and steps in the devel-
opment of CDI. Starting with healthy microbiota, antibiotic alterations lead to a susceptible state where C. difficile spores can enter
and germinate. This leads to colonization and infection. Toxin production can then trigger inflammation and cytotoxic/cytopathic
effects on the mucosa, leading to colitis and severe disease. Red boxes and arrows indicate therapies aimed at preventing C. difficile
infection. Green boxes and arrows indicate therapies aimed at treating primary CDI and reducing disease severity. Blue boxes and
arrows indicate therapies aimed at reducing and treating recurrent CDI. IVIG, intravenous immunoglobulin.
patients). The vaccination schedule consisted of
intramuscular injections into alternating deltoid
regions at days 0, 7, and 28. The results again showed
that it induced seroconversion in up to 83% of par-
ticipants for antibodies against both toxins A and B,
and up to 97% against toxin A alone.57 If successful,
VLA84 and similar vaccinations would be poten-
tial preventative treatments that could be given
to high-risk populations to protect against future
CDIs.
ACAM-CDIFFTM is a vaccine against toxins A
and B developed by Sanofi that is given parenter-
ally. It was found to be safe in adults and elderly
patients in two phase I trials (NCT00127803 and
NCT00214461).58 The optimal dosing was tested in
phase II trials, with one finding that giving a high
dose with adjuvant (100 g antigen + AlOH) at
0, 7, and 30 days resulted in the greatest immune
response.59 A phase III trial (NCT01887912) was
discontinued and the vaccine research as a whole
was discontinued by Sanofi following a discourag-
ing interim analysis.60
PF-06425090 is a vaccine developed by Pfizer
composed of genetically modified toxins A and B
from C. difficile.61,62 The drug has completed mul-
tiple phase I and a single phase II trial so far, with
another phase II trial active (NCT02561195) and a
phase III trial (NCT03090191) currently recruiting.
The current phase II trial has three groups: high-
dose (200 g) vaccine, low-dose (100 g) vaccine,
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and placebo. In addition, these three groups are split
into two vaccination schedules. The vaccine is given
ina three-dose vaccination scheduleby0.5mL intra-
muscular injection. The first vaccination schedule is
days 1, 8, and 30 and the second schedule is months
0, 1, and 6. Results from this phase III trial are
currently being reported, with an indication that
the vaccination is leading to increased antitoxin A
antibody titers, although no statistical analysis has
been performed yet. Further study is required to test
its efficacy in preventing CDI.
CDVAX is a novel oral vaccine against C. dif-
ficile that utilizes spores from a genetically modi-
fied bacterium to produce an oral vaccine that may
induce strong mucosal immunity. This differs from
injectable vaccines as the antigens will be presented
from the mucosal side of the GI tract. Recently, a
phase I trial (NCT02991417) for CDVAX vaccina-
tion againstC. difficilewas terminated.More clinical
research is needed to test the efficacy and safety of
CDVAX.63
Lactoferrin therapy. For CDI to develop, C. dif-
ficile has to colonize the intestines and produce
mucosal damage leading to symptoms such as diar-
rhea. If therapies are developed to target C. diffi-
cile growth, toxin production, andmucosal damage,
CDI can be prevented even if the intestinal micro-
bial community is disrupted (Fig. 5). Elevated lev-
els of fecal lactoferrin and increased WBC count
have been shown to be associated with increased
CDI severity.64 Utilizing rat intestinal epithelia cells
(IEC-6), Otake et al. showed that lactoferrin has
the potential to reduce the cytotoxic damage of
C. difficile toxin B.65 In an in vitro chemostat gut
model, Chilton et al. showed that lactoferrin delays
C. difficile growth and reduces toxin production.66
There are currently two recruiting clinical tri-
als testing lactoferrin. The first (NCT02626104) is
looking at using lactoferrin prophylactically dur-
ing initial antibiotic usage for pediatric patients to
reduce antibiotic-associated diarrhea. In this study,
children will receive either 100 mg of oral lactofer-
rin twice daily for the duration of antibiotic treat-
ment or they will receive a placebo of 100 mg of
oral maltodextrin twice daily. The second study
(NCT00377078) is looking at the use of lactofer-
rin to prevent CDIs in long-term care patients with
feeding tubes who require broad-spectrum antibi-
otics. In this study, patients in the treatment armwill
be given lactoferrin at a concentration of 5 mg/mL
during the enteral feeding system flush cycle, con-
sisting of 600 mL per day. This will be started at the
beginning of the first day of antibiotic treatment and
continued 8weeks following the last antibiotic dose.
The results from this study will hopefully determine
if lactoferrin will prove to be an effective treatment
worthy of additional study.
Treatment of primary CDI: reducing severity
and increasing clinical cure
If the onset of CDI cannot be prevented, additional
emerging therapies are needed to reduce mucosal
damage, disease severity, and the risk of recurrence.
As thehighestmortality is associatedwith severe and
complicated CDI, therapies given shortly after the
diagnosis of CDI, which aim to reduce the burden of
C. difficile cells and toxins, reduce toxin damage at
themucosal barrier, andhelp restore themicrobiota,
can potentially reduce the progression to severe and
complicated CDI (Table 2).
Antibiotics. One area of interest is the develop-
ment of new narrow spectrum antibiotics that have
less of an effect on native bacteria. This would
allow for the native bacteria to recolonize and
re-establish during CDI therapy, potentially reduc-
ing disease severity and reducing recurrence in the
future (Fig. 5). Additionally, some CDI cases are
resistant to standard antimicrobial therapy, necessi-
tating the development of novel antibiotic therapies
for treating these resistant cases.
Cadazolid is a hybrid fluoroquinolone-
oxazolidinone antibiotic produced by Actelion
Pharmaceuticals Ltd that acts by inhibiting protein
synthesis and to some extent inhibiting DNA
synthesis.67 In phase I trials, cadazolid was well
tolerated and minimally absorbed, with high con-
centrations found in stool.68,69 Cadazolid inhibits
sporulation, toxin production, and is bactericidal.
A phase II trial (NCT01222702) studied the effec-
tiveness of different doses of cadazolid compared
with vancomycin in patients with CDI. The four
treatment groups were: 250 mg cadazolid twice
daily (20 patients), 500 mg cadazolid twice daily
(22 patients), 1000 mg cadazolid twice daily (20
patients), or 125 mg vancomycin four times daily
(22 patients). All treatments were given for 10 days.
In this study, cadazolid treatment showed lower
recurrence rates compared with vancomycin treat-
ment (18–25% compared with 50% recurrence)
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and cadazolid showed higher sustained clinical cure
rates (46.7–60% compared with 33.3%). There was
no evidence for an effect of dosage of cadazolid. In
addition, cadazolid treatment was well tolerated.70
Two phase III studies have been completed, with a
third currently suspended. The recently completed
phase III trials are being analyzed for efficacy, with
one appearing to achieve the primary endpoint and
the other failing to meet the primary endpoint of
clinical cure rate.71 The formal analysis of these two
studies will be needed to determine the efficacy of
cadazolid for the treatment of CDI.
CRS3123 (REP3123) is a novel narrow-spectrum
antibiotic produced by Crestone Inc. that acts
by inhibiting bacterial methionyl-tRNA synthetase,
with high activity against Gram-positive bacte-
ria and C. difficile but low activity against Gram-
negative bacteria.72,73 CRS3123 was reported to
reduce spore formation and toxin formation in a
hamster model.74 One phase I trial found CRS3123
to be well tolerated at multiple doses (100, 200, 400,
800, and 1200 mg) and the indicated safety of the
drug supported further research into its efficacy.72
Further research is necessary to test the efficacy of
CRS3123 for the treatment of CDI.
LFF571 is a semisynthetic thiopeptide produced
by Novartis Pharmaceuticals that acts on Gram-
positive bacteria by blocking protein synthesis.75
In a phase II study (NCT01232595) completed in
2013, LFF571 was found to be minimally absorbed
and had high retention in the intestines.76 In this
study, adults experiencing primary or first recur-
rent CDI were randomized to receive either LFF571
(200 mg) or vancomycin (125 mg) four times daily
for 10 days. LFF571 had a noninferior clinical cure
rate (90.6%) compared with vancomycin (78.3%),
with a potential to have a lower recurrence rate (19%
versus 25%).77 LFF571 treatment had more adverse
events than vancomycin (76.1% versus 69.2%) but
had less adverse events suspected to be related to the
treatment (32.6% versus 38.5%).
MCB3681 is a hybrid fluoroquinolone-
oxazolidinone produced by Morphochem that
has a water-soluble prodrug formulation termed
MCB3837 that can be given by IV, making this
therapy an option for severe and complicated C.
difficile infections when oral therapy fails. It has
been shown to have activity against Gram-positive
bacteria, including C. difficile, but limited activity
against Gram-negative bacteria such as those native
to the human gut.78–80 A phase I study where 12
healthy volunteers were given daily intravenous
infusions of 6 mg/kg MCB3837 over 12 h for 5 days
showed little impact on microbiota and suggested
the drug was well tolerated.81 Phase II/III trials are
being planned currently, and the U.S. Food and
Drug Administration (FDA) designated MCB3837
as a Qualified Infectious Disease Product for the
treatment of CDI.82
Nitazoxanide is believed to be a non-
competitive inhibitor of the pyruvate ferre-
doxin/flavodoxin oxidoreductases produced by
Romark Pharmaceuticals.83 Currently, nitazoxanide
is FDA approved for treatment of cryptosporidiosis
and giardiasis, and is given by tablet orally (500mg)
every 12 h for 3 days, with possible adverse side
effects of abdominal pain, nausea, headache, or dis-
colored urine.84 Nitazoxanide (500 mg twice per
day for 7 or 10 days) was shown to have similar
clinical cure and recurrence rates for CDI versus
vancomycin (125mg four times per day for 10 days)
and metronidazole (250 mg four times per day for
10 days).85,86 However, nitazoxanide is more expen-
sive thanmetronidazole, limiting its use for primary
CDI.87 A phase III trial (NCT00304356) with results
currently being reported is looking at the use of
nitrazoxanide (500 mg twice daily) as a treatment
for CDI that has failed to be cured bymetronidazole
or vancomycin.
Ramoplanin is a glycolipodepsipeptide that
disrupts cell wall biosynthesis by binding to
peptidoglycan.88 It has been shown to be nonab-
sorbable, and to bind to spores and kill vegetative
C. difficile cells in vitro. This may indicate a poten-
tial use for ramoplanin as a preventative measure
to reduce risk of initial disease or reduce recur-
rence by binding to spores and then killing the
ones that germinate.89 A phase II trial compar-
ing treatment using ramoplanin versus vancomycin
for CDI showed similar clinical response rates with
400 mg ramoplanin (71% versus 78%) and simi-
lar sustained clinical response rates (83% 200 mg
ramoplanin, 85.2% 400 mg ramoplanin, and 85.7%
vancomycin). A phase III clinical trial has been
approved by the FDA.
Ridinilazole (SMT19969) is a narrow-spectrum,
nonabsorbable novel antibiotic produced by
Summit Therapeutics that potentially impacts cell
division, though the mechanism is still not fully
understood.90 A phase I trial studied the safety
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of oral doses of up to 2000 mg of ridinilazole.
Ridinilazole was shown to have minimal effects
on the microbiota and was not measured at high
serum levels in this phase I trial.91 A phase II trial
with 100 patients with CDI compared a 10-day oral
ridinilazole treatment (200 mg every 12 h) with a
10-day oral vancomycin treatment (125 mg every
6 h). This trial showed that ridinilazole caused a
higher sustained response rate compared with van-
comycin (67% versus 42%) as well as a reduction
in recurrence (14.3% versus 34.8%).92 There were
no adverse events that necessitated discontinuation
of ridinilazole, and the adverse events were similar
between ridinilazole and vancomycin treatment.
An additional phase II trial (NCT02784002) was
completed in 2016 comparing ridinilazole to
fidaxomicin; study results are being analyzed.
Surotomycin (CB-183,315) is a bactericidal cyclic
lipopeptide originated by Cubist Pharmaceuticals
and currently developed by Merck & Co that acts
to dissipate the membrane potential of C. difficile.93
Surotomycin given to two treatment groups, either
at 125 mg twice daily or 250 mg twice daily for
10 days, was shown in a phase II trial to reduce
recurrence of C. difficile infection compared with
vancomycin that was given at 125 mg four times
daily for 10 days.94,95 In this phase II trial, adverse
events were similar between both surotomycin arms
and the vancomycin arms. However, surotomycin
(250mg given orally twice daily for 10 days) failed to
achieve noninferiority versus vancomycin (125 mg
given orally four times daily for 10 days) in a recent
phase III trial (NCT01597505), with initial cure
rates of 79% versus 83.6% and sustained clinical
response rates of 60.6% versus 61.4%.96 An addi-
tional phase III trial (NCT01598311) was recently
completed studying the effectiveness of surotomycin
treatment (285 patients; 250 mg twice daily for
10 days) comparedwith vancomycin treatment (292
patients; 125 mg vancomycin four times daily for
10 days) for patients with confirmed CDI. The
study showed that surotomycin was noninferior
to vancomycin for clinical response at the end of
the trial (83.4% versus 82.1%), but surotomycin
failed to demonstrate superiority to vancomycin in
clinical response over time and sustained clinical
response.97
Tigecycline is a glycylcyline produced by Pfizer
that acts by binding to the 30S ribosomal sub-
unit and inhibiting protein translation by block-
ing tRNA molecules from entering the A site of
the ribosome.98 It is FDA approved for treatment
of community-acquired pneumonia (100 mg by IV
once, with 50 mg IV given every 12 h thereafter for
7–14 days), complicated skin/subcutaneous infec-
tion (same dosing but for 5–14 days), and compli-
cated abdominal infections (same dosing but for
5–14 days).99 Tigecycline has cured CDI in case
reports; however, pooled data may indicate an asso-
ciation with higher mortality.100,101 An interven-
tional clinical trial (NCT01401023) where patients
received standard C. difficile–associated diarrhea
treatment of vancomycin ormetronidazole with the
addition of IV tigecycline (100 mg once, followed
by 50 mg IV every 12 h after) for the duration of
hospitalization (approximately 7–14days)was com-
pleted in 2013, with findings on clinical cure not yet
reported. A recent retrospective observational study
found tigecycline combination therapy with van-
comycin ± metronidazole to be safe and effective
for the treatment of severe–complicated CDI.102
Toxin binders. Toxin binders are molecules that
have been shown to sequester toxins, and some have
the additional ability to bind to proinflammatory
factors. While current studies into the use of toxin
binders to treat CDI have not proven successful to a
large extent, it is important to consider them as they
could potentially be effective if the right formula-
tion is discovered. Given orally, these binders enter
the lumen and can be used during CDI to reduce
the mucosal damage done both by the toxins and
by the host immune response. In this way, binders
have the potential to reduce disease severity, hope-
fully lowering the number of cases of severe and
complicated CDI cases (Fig. 5). However, these
binders could also bind pharmaceuticals, so they
should not be coadministered with standard ther-
apy if found to bind to standard drugs.21 As this is
an important consideration, newer binders aim to
reduce pharmaceutical cross-binding.
Calcium aluminosilicate antidiarrheal
(CASADTM), developed by Salient Pharma-
ceuticals, has been shown to sequester C. difficile
toxins A and B with limited off-target protein
binding.103 Similar to other binders, if CASAD can
preferentially bind to C. difficile toxins without
binding to antibiotics, then this could reduce the
severity of disease and potentially reduce recurrence
risk. A phase II trial (NCT01570634) attempting to
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study the effectiveness of adding CASAD given in
500 mg capsules orally three times daily for 14 days
to standard CDI treatment was terminated for
low enrollment; however, the authors describe the
potential of calcium aluminosilicate to bind TNF-,
IL-1, IL-6, and IL-10, which could theoretically help
reduce the immune response to the infection and
decrease fever and leukocytosis. Further research
is needed to study the effectiveness and safety of
CASAD for CDI treatment.
GT267-004 (tolevamer) is a polystyrene binder
developed by Sanofi that is proposed to sequester
C. difficile toxins A and B. It was shown in a phase II
trial to be noninferior to vancomycin treatment
for mild-to-moderate CDIs, with the potential to
reduce recurrence.104 However, the analysis of two
phase III trials showed that tolevamer (563 patients
received 9 g loading dose followed by 3 g every
8 h for 14 days) was inferior to both metronidazole
(289 patients received 375 mg every 6 h for 10 days)
andvancomycin (266patients received125mgevery
10 h for 10 days) for clinical cure of CDI (44.2%,
72.7%, and 81.1%, respectively).40 Adverse events
were similar across the three treatment groups. A
third phase III trial (NCT00466635) was terminated
and it is doubtful that additionaldevelopmentof this
compound will be pursued.
GT160-246 is a high molecular weight soluble
anionic polymer produced by Sanofi that has been
shown in hamsters to reduce mortality from CDI,
and in vitro data suggest GT160-246 can neutralize
the activity of toxins A andB.105 AGT160-246 phase
I trial showed it to be safe and well tolerated. A
phase II trial (NCT00034294) comparing GT160-
246 to vancomycin for the treatment of C. difficile–
associated diarrhea was completed, with results not
currently posted.
Host responsemodulation. One target for reduc-
ing disease severity as previously mentioned is
regulating the host response in order to reduce
host-derived mucosal damage during CDI treat-
ment. Alanyl-glutamine is a dipeptide that has been
shown tohave potential therapeutic effects in reduc-
ing C. difficile toxin damage in intestinal epithe-
lial cells (Fig. 5). Rodrigues et al. showed that
alanyl-glutamine reduces apoptosis and increases
intestinal cell proliferation in mouse intestinal cells
(IEC-6) when exposed to C. difficile toxin B.106
Santos et al. additionally showed in IEC-6 cells
that alanyl-glutamine treatment reducedTcdAtoxin
damage and increased RhoA expression, suggesting
a potential explanation for the protective effects.107
Using intestinal loop models, Warren et al. showed
that treatment with ATL 370 (an adenosine A2A
receptor agonist) and alanyl-glutamine reduced ileal
secretions, apoptosis, mucosal injury, and levels of
KC and IL-10 after C. difficile toxin A exposure.108
A phase II clinical trial (NCT02053350) testing the
efficacy of alanyl-glutamine as a supplement (44 g
orally daily for 10 days) during treatment of CDI
was terminated due to low enrollment. Further clin-
ical trials are needed to test the efficacy of alanyl-
glutamine in treating primary CDIs and reducing
disease severity.
Antibodies. As disease is caused by the toxins
produced from C. difficile, one potential goal dur-
ing primary therapy is the neutralization of toxins
with antitoxin antibodies. While specific mono-
colonal and polyclonal antibodies are being studied
for their effectiveness in preventing recurrence
(as discussed in the recurrence section), intra-
venous immunoglobulin (IVIG) and serum bovine
immunoglobulin (SBI) have been proposed to
reduce disease severity by reducing toxin dam-
age (Fig. 5). A phase IV trial (NCT00177970)
looking at IVIG (400 mg/kg infused over 4–6 h)
effectiveness during standard therapy for severeCDI
was terminated because it was unable to receive
IVIG for free. There is a currently active clinical trial
(NCT02730325) studying the effects of giving SBI
(10.0 g twice per day) on ulcerative colitis in patients
who tested positive for C. difficile and who are on
vancomycin. Further study is needed to determine
the efficacy of IVIG or SBI during severe CDI.Mon-
oclonal and polyclonal antibodies directed against
C. difficile are an alternative that requires fur-
ther study for their effectiveness during therapy of
CDI.
Additionally, IMM-529 is a polyclonal antibody
developed by Immuron that has shown cross-
reactivity with C. difficile vegetative cells, spores,
and toxin B. IMM-529 is currently being tested in
a phase I/II trial (NCT03065374) for the treatment
of CDI.109 The study aims to determine the safety
and tolerability of IMM-529. Patients will receive
standard of care treatment for CDI in addition to
either IMM-529 (1000 mg orally three times daily)
or placebo.
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Bowel prep. One method of reducing C. difficile
cell and toxin burden is to flush the luminal content
out of the intestines using bowel preps after CDI
is diagnosed and before standard therapy (Fig. 5).
NuLYTELY R© is a formulation of the osmotic
laxative PEG 3350 and electrolytes produced by
Braintree Laboratories.110 A recruiting phase IV
clinical trial (NCT01630096) will study the effi-
cacy of oral lavage by giving NuLYTELY after the
diagnosis of CDI, before antibiotics are started. In
this study, patients testing positive for CDI will be
assigned to either a control groupor theosmotic lax-
ative group inwhich theywill be given the PEG 3350
solution in 8oz volume every 10 min until 6 L are
ingested. An additional 2 L may be ordered if neces-
sary. Both groups will then receive standard of care
antibiotic treatments. Further results are needed to
determine if oral lavage before standard treatment
will reduce disease severity by lowering the C. diffi-
cile bacterial and toxin load in the GI tract.
Preventing and treating recurrent CDI
With a median recurrence of 21% and a high rate
of readmissions and cost associated with recurrent
CDI, developing novel therapies to prevent recur-
rence and treat recurrent CDI will have a substan-
tial impact on patient morbidity, as well as on the
healthcare burden of CDI.111,112 There are two dis-
tinct treatment goals concerning recurrent CDI that
could be optimized further. The first is reducing
initial recurrence in patients experiencing primary
CDI, and the second is treating therapy-resistant
patients who are experiencing multiple episodes of
recurrent CDI. As mentioned in the primary ther-
apy section,manyof the emerging antibiotics poten-
tially offer a reduction in recurrence risk following
standard therapy, including ridinilazole, LFF571,
MCB3681, and ramoplanin. Additionally, probi-
otics used for prevention could potentially be also
used to help recover the natural microbiota follow-
ing standard therapy (Table 3).
For the second goal, with subsequent recurrence
risk increasing after each unsuccessfully treated
recurrent episode, it is important to develop novel
therapies that specifically treat recurrent-prone
CDI. While FMT has been shown to be effective
at treating recurrent CDI and preventing further
recurrences, human-derived fecal matter is diffi-
cult to standardize and has multiple potential risks,
including the transfer of infectious material and
long-term consequences of inoculating the gut with
foreign fecal material. As such, research is ongoing
to develop new agents for treating recurrent CDI.
These agents include antibodies directed against
C. difficile cells and toxins, as well as standard-
ized bacterial replacement cultures and mixtures
(Table 3).
IV antibodies. Researchers have found an inverse
correlation between the development of recurrent
disease and antitoxin antibody levels.54,55 Antibod-
ies given intravenously enter the lumen in regions
of mucosal damage and help lower the intestinal
damage caused by toxins. This may help increase
the recovery of the healthy mucosal layer and assist
in the recovery of the natural microbiota, leading to
restoration of colonization resistance (Fig. 5).
Actoxumab is a human monoclonal antibody
against C. difficile toxin A and bezlotoxumab (MK-
6072-001) is a humanmonoclonal antibody against
toxin B developed by Merck. Two phase III clin-
ical trials (MODIFY I and MODIFY II) studied
the ability of these two antibodies to reduce the
recurrence of CDI in 2655 patients. In these tri-
als, it was shown that the addition of bezlotoxumab
(10 mg/kg infusion) to the standard of care antibi-
otics for primary or recurrent C. difficile infections
resulted in a lower rate of recurrence compared
with the placebo (MODIFYI: 17% versus 28%;
MODIFY II: 16% versus 26%) and a higher sus-
tained clinical cure comparedwith theplacebo (64%
versus 54%). The addition of actoxumab (10 mg/kg
infusion) alone did not decrease recurrence, and in
combination with bezlotoxumab (10 mg/kg infu-
sion of both bezlotoxumab and actoxumab) it did
not increase efficacy compared with bezlotoxumab
alone.113 The adverse event rateswere similar among
the treatment groups. These results indicate that
antibodies targeted against toxin B are a poten-
tial therapy for reducing recurrence in high-risk
patients. A recent computer model–based analy-
sis has predicted that bezlotoxumab will be cost-
effective for the prevention of recurrence in patients
receiving standard of care antibiotics for CDI.114,115
A new phase III trial (NCT03182907) studying the
effects of bezlotoxumab (10 mg/kg infusion) in
addition to standard antibacterial treatment in chil-
dren with C. difficile infections is currently recruit-
ing. Bezlotoxumab (10 mg/kg infusion) is currently
FDA approved for the prevention of recurrent CDI
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in patients currently on treatment for CDI and who
are at high risk for recurrence.116
Polyclonal oral antibodies. Unlike IV antibod-
ies, which enter through the bloodstream, oral
antibodies enter the GI lumen directly. If
polycolonal antibodies are used, the oral antibodies
can be designed to target not only toxins but also
spores and vegetative cells. By reducing the burden
of spores and vegetative cells, these treatments can
reduce the chance of recurrence. Through neutral-
ization of toxins, these therapies can additionally
protect against C. difficile toxin damage, assisting
in the restoration of the mucosa and microbiota
(Fig. 5).
Colostrum is a type of milk produced during
pregnancy that has high levels of antibodies to
provide passive immunity to infants. Immuniza-
tion of pregnant mares and cows with C. diffi-
cile proteins results in the production of antibod-
ies that can be obtained from the colostrum and
used therapeutically. Colostrum frommares immu-
nized with toxins A and B binding domains was
able to block the cytotoxic activity of the C. diffi-
cile toxins A and B.117 Repeated immunization of a
pregnant cow with recombinant mutants of toxin
A and B produced hyperimmune bovine colostrum
(HBC) that was able to reduce the disease sever-
ity of CDI in piglets.117 Similarly, HBC was shown
to prevent, treat, and reduce recurrence of CDI
in mouse models.118 A phase II/III clinical trial
(NCT00747071) to test the efficacy and safety of
colostrum-derived antibodies for the prevention
of CDI was withdrawn. Further clinical trials are
needed to assess the ability of colostrum-derived
antibodies to prevent, treat, and reduce recurrence
of CDI.
MucoMilk R© is a whey protein concentrate 40%
(WPC-40) enriched with polyclonal-antibodies
developed by MucoVax that is produced from
the milk of cows immunized with formaldehyde-
inactivated C. difficile cells and toxin filtrate. As it
is given orally, the antibodies will be available on
the luminal side and have the potential to target
spores, vegetative cells, and toxins. In a hamster
model, hamsters infected with C. difficile died when
untreated with WPC-40, while hamsters treated
with WPC-40 had an 80–90% survival, depend-
ing on the formulation. In preliminary data, 16
patients with CDI were given WPC-40 three times
daily for 2 weeks following standard antibiotic ther-
apy. TheWPC-40was well tolerated and none of the
patients experienced recurrence (median follow-up:
333 days, range: 35 days–1 year).119 A 60-patient
phase II/III trial (NCT00177775) testing the effi-
cacy and safety of MucoMilk in the prevention of
recurrence of C. difficile was completed in 2005 and
results are not posted yet. Further study is required
to test the benefit of MucoMilk following standard
antibiotic therapy to prevent recurrence.
Bacterial replacement. While the exact reason for
the loss of colonization resistance is unknown, com-
prehensive bacterial replacement during FMT has
shown that restoration of certain components of
the microbiota is effective in treating recurrence.
Decreased microbial diversity is associated with
recurrent disease.120 Future research is needed to
find the specific community members needed to
restore colonization resistance. Emerging therapies
are being developed to address this aimwith the goal
of standardized bacterial replacement therapeutics
to restore the natural microbiota (Fig. 5).
SER-109 is a capsule consisting of bacterial spores
derived from screenedhumandonor stool. The FDA
designated SER-109 as a Breakthrough Therapy and
Orphan Drug.121 Khanna et al. found that SER-
109 potentially prevents CDI recurrence within an
8-week follow-up period in patients experiencing
recurrence, presumably through diversification of
the gutmicrobiota and recovery of natural coloniza-
tion resistance.122 A phase II (ECOSPOR) double-
blind, placebo-controlled trial enrolled 89 patients
with multiple recurrent CDI to test the safety and
efficacy of SER-109 to reduce recurrence of CDI.
After patients had completed antibiotic therapy for
CDI, they were split into SER-109 (59 patients) and
placebo (30 patients) groups. The SER-109 group
received one oral dose of SER-109 (1 × 108 bacte-
rial spores) after completion of antibiotics, while the
other received the placebo. Results from the phase II
(ECOSPOR) trial indicate that SER-109 did not
meet the primary endpoint for reducing CDI
recurrence overall. However, in high-risk popu-
lations (in this case, those 65 years or older),
SER-109 treatment showed reduced recurrence
rates (45% versus 80% recurrence risk).123 Two
phase III trials (ECOSPOR III–NCT03183128
and ECOSPOR IV–NCT03183141) are currently
recruiting.
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Seres TherapeuticsTM is also developing another
oral microbiome therapeutic called SER-262, which
is a manufactured microbial therapeutic that, in
contrast to SER-109, is a definedmicrobial commu-
nity consisting of the spores of anaerobic, commen-
sal bacteria produced by in vitro fermentation and is
not an undefined consortium derived from human
stool. SER-262 is currently being tested in a phase I
trial (NCT02830542) for adult patients to prevent
recurrent C. difficile infection. In this trial, patients
receiving standard of care antibacterial treatment
for primary CDI will be assigned to experimental
groups with single doses ranging from 1 × 104 to
1 × 108 CFUs or multiple doses ranging from 1 ×
107 to 1 × 108 CFUs. This study will examine the
safety, tolerability, and the efficacy of SER-262 to
prevent CDI recurrence.
CBM588 R© is a probiotic consisting of Clostrid-
ium butyricum produced by Osel that is given by
oral administration. C. butyricum lacks toxins asso-
ciated with CDI and has been shown to be safe.124 A
phase II trial (NCT01077245) testing for the ability
of CBM588 to reduce recurrence after CDI therapy,
in which patients with confirmed CDI will receive
standard of care antibacterial therapy in addition
to either CBM588 (2 g per dose) or placebo twice
daily for 42 days, was suspended for lack of enroll-
ment. Future clinical studies need to be performed
to test the efficacy of CBM588 in preventing CDI
recurrence.125
MET-2 (Microbial Ecosystem Therapeutics 2)
consists of a live microbe community derived from
healthy donor stool developed by NuBiyota. A small
20-patient phase I pilot study (NCT02865616) is
currently recruiting to test the safety and efficacy
of MET-2 in treating recurrent CDI in patients
who have experienced at least two prior C. diffi-
cile episodes. In this study, patients who are expe-
riencing a case of recurrent CDI will be given an
initial loading dose of MET-2 over 2 days and then
a maintenance dose of MET-2 over 8 days. If the
patients do not respond to the first loading dose,
they can be offered a second, higher dose of MET-
2. Patients experiencing failure of the second dose
may be offered a higher dose given by colonoscopy.
Further research will be needed to test its safety and
efficacy in preventing recurrence of CDI.
RBX2660 is a stool-derived standardized therapy
consisting of a live bacteria suspension developed
by Rebiotix R©. The suspension is given by reten-
tion enema and is derived from healthy donors. A
phase II trial in patientswith at least two recurrences
of CDI found it to be safe and efficacious, with
87.1% of patients (27 of 31) achieving treatment
success after one or two treatments.126 Two phase II
trials (NCT02589847 and NCT02299570) are cur-
rently active but not recruiting, and a phase III
trial (NCT03244644) is currently recruiting to study
the efficacy of RBX2660 in the treatment of recur-
rent CDI. Results for an open-label phase II
trial (PunchTM Open Label) were announced in
April 2017, indicating a success rate of 78.8% for
RBX2660 compared with the historical control of
51.8% for the prevention of recurrent C. diffi-
cile infections.127,128 The results of the active clin-
ical trials will help address the relevant efficacy of
RBX2660. Rebiotix has also made a lyophilized oral
formulation of RBX2660 termed RBX7455, which
is stable at room temperature. RBX7455 is currently
being tested in a phase I study for the prevention
of recurrent C. difficile infection, and the study was
recently expanded.129,130
CP101 is an orally administered capsule con-
taining freeze-dried microbes derived from healthy
human donors and was developed by Finch. The
FDA has recently granted CP101 the Fast Track des-
ignation for the treatment of recurrent CDI.131 In
a pragmatic cohort study, 49 patients experiencing
recurrent CDI were given encapsulated lyophilized
fecal microbiota (dosing ranged from 2.5 × 1012
bacteria in 24–27 capsules to 1.25 × 1012 bacte-
ria in two to three capsules). This initial study
observed an 88% (43 of 49) clinical success rate
defined as no recurrent episodes over 2 months fol-
lowing therapy.132 CP101 is currently being tested
in a recruiting phase II clinical trial (NCT03110133)
for the treatment of recurrent CDI.
Nontoxigenic C. difficile. Similar to bacterial
replacement, one emerging therapy is utilizing non-
toxigenic C. difficile to outcompete toxigenic C. dif-
ficile and prevent recurrent disease while the native
microbiota recovers (Fig. 5). This therapy may also
be useful for prevention of CDI, similar to pro-
biotics. The current clinical trials are looking at
using nontoxigenic C. difficile for prevention or
recurrence.
VP20621 (NTCD-M3) consists of spores from
the nontoxigenic C. difficile strain M3. This strain
has been shown to be protective in hamsters
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against C. difficile challenge. A study in healthy
adults showed that VP20261 was well tolerated and
resulted in colonization of the GI system following
pretreatment with vancomycin.133 A phase II trial
sponsored by Shire studied the safety and efficacy of
VP20261 for the prevention ofC. difficile in patients
experiencing initial CDI or a first recurrence.
Patients were assigned to four groups receiving oral
liquid VP20261 formulation of 104 spores per day
for 7 days (43 patients), 107 spores per day for 7 days
(44 patients), 107 spores per day for 14 days (42
patients), or placebo for 14 days (44 patients). This
study found that VP20261 was able to colonize the
GI tract of patients following successful treatment
with metronidazole or vancomycin and treatment
was well tolerated. Additionally, VP20261 treatment
resulted in reduced recurrence of CDI, with 13 of
43 patients experiencing recurrence in the placebo
arm and 14 of 125 experiencing recurrence in
the VP20261 treatment groups. Of the patients
receiving VP20261, recurrence was 2% for patients
who were successfully colonized (2 out of 86)
compared with a recurrence of 31% for patients
not successfully colonized (12 out of 39).134
Bile acid supplementation. As particular sec-
ondary bile acids have been shown to be inhibitory
to vegetative C. difficile, one possible therapy would
be supplementation with secondary bile acids dur-
ing CDI treatment.12–14 This could reduce the levels
of C. difficile in the gut by suppressing growth and
lead to a decreased rate of recurrence. A currently
recruiting, phase IV clinical trial (NCT02748616)
will study the effects on the rates of CDI recur-
rence for urodeoxycholic acid (300 mg) supple-
mentation for 2 months in total given during and
following standard CDI treatment. Urodeoxycholic
acid is being used as a surrogate for deoxycholic
acid, a secondary bile acid.
Summary of emerging CDI therapies
CDI causes significant morbidity and mortality
while also placing a substantial burden on the
healthcare system. We currently have effective ther-
apies for primary and recurrent infections, but there
is still significant improvement to be had in the areas
of prevention, disease severity reduction, recurrence
prevention, and treatment of recurrent CDI.
With an incidence reaching nearly 500,000 cases
annually in the United States, there is a substan-
tial need for directed CDI prevention therapies for
susceptible patients. Already emerging therapies are
being utilized in the clinic, with probiotics such
as BioK and VSL#3 as examples. The main tar-
gets for preventative measures are reducing the ini-
tial microbial disruption (-lactamases or reduced
systemic antibiotics), restoring the microbiota with
probiotics (BioK and VSL#3), or reducing the abil-
ity of C. difficile to grow and thrive by directly tar-
geting it with vaccinations (VLA84, ACAM-CDIFF,
PF-06425090, and CDVAX) and growth modula-
tors such as lactoferrin. With continued clinical
trials and development of preventative therapies,
reduction of CDI incidence may soon be in reach,
with significant ameliorating effects on the CDI
healthcare burden, patient morbidity, and patient
mortality.
Once CDI has developed in a susceptible patient,
the clinical goals shift to reducing severity, pre-
venting fulminant CDI, obtaining clinical cure, and
lowering recurrence risk. Development of effective
toxin binders (calcium aluminosilicate, GT267-004,
and GT160-246) and immune modulators (alanyl-
glutamine), which help to reduce the toxin dam-
age caused by C. difficile and restore the mucosa,
may prevent severe CDI from developing and aid
in the recovery of colonization resistance. Vaccina-
tions,while seen as amethodof prevention,may also
act to decrease CDI severity by potentially reduc-
ing C. difficile organism burden and toxin activity.
Bowel prep solutions that reduce luminal toxin lev-
els and C. difficile organism burden may also help
prevent severe CDI and increase therapeutic effi-
cacy (NuLYTELY). The development of antibiotics
that areminimally absorbed and reach high luminal
concentrations with high activity against C. difficile
without broad activity against other native bacte-
ria is promising for the therapy of CDI (cadazolid,
CRS3123, LFF571, MCB3681, nitazoxanide, ramo-
planin, ridinilazole, surotomycin, and tigecycline).
The reduced activity against native bacteria may
allow for more rapid recovery, potentially leading
to a lower severity and a decreased recurrence risk.
Even with effective therapy, elevated recurrence
risk still persists for months after successful clinical
cure. With each recurrence, the risk of subsequent
recurrence increases.111 While novel antibiotics are
utilized to reduce the risk of CDI recurrence during
primary treatment and may have a role in treating
recurrent disease, additional therapies are needed
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to target the restoration of colonization resistance.
The emerging use of monoclonal and polyclonal
antibodies against C. difficile has shown success in
reducing the risk of recurrence when given with
standard CDI therapy. Determination of the best
toxin motifs and which other C. difficile spore and
vegetative cell molecules to target will help increase
the effectiveness of toxin neutralization and C. diffi-
cile clearance following therapy. These treatments
could also potentially be utilized for prevention
and during therapy to reduce severity, although
directed clinical trials are needed to assess this pos-
sibility. Aside from lowering mucosal damage done
by toxins and C. difficile, restoration of coloniza-
tion resistance can be achieved by supplementing
the microbiota with bacterial replacement thera-
pies (SER-109, CBM588, MET-2, RBX2600, and
CP101). Alternatively, or in unison, nontoxigenicC.
difficile (VP20261) can be administered in order to
compete with toxigenic C. difficile cells and spores
that may be remaining in the GI tract or reintro-
duced during the high-risk few months following
CDI therapy.
Future directions: perspectives
While large strides are being taken toward effec-
tive prevention, primary treatment, and recurrence
reduction, there are still gaps in our knowledge of
CDI pathogenesis that would help direct therapy
research if elucidated. For the prevention of CDI,
research is currently underway inmany laboratories
and fields to identify the exact species and micro-
bial interactions necessary to produce colonization
resistance against C. difficile and what alterations to
the GI microbiota lead to an increase in CDI risk.
If these questions can be answered, specific bac-
terial replacement that is purified to only include
nonpathogenic bacteria can be used to restore col-
onization resistance and reduce CDI rates. Addi-
tionally, if the specific alterations are known for the
increased risk of CDI, such as the loss of keystone
species, tests can be developed to monitor patients
receiving systemic antibiotics or those at high risk
demographically to determine if preventative thera-
pies are needed, reducing cost by targeting the use of
these preventative treatments to only those requir-
ing them.
For primary therapy, the direct mechanism lead-
ing to the development of severe and compli-
cated CDI needs to be determined to develop
targeted therapies for lowering severity. For
instance, if mucosal damage is in part caused by
immune response, then immune modulators can
be utilized to reduce mucosal damage and protect
against severe and fulminant CDI. Additionally, if
loss of specific members of the microbiota, C. diffi-
cile burden, or specific immune states are associated
with the development of severe and fulminant CDI,
these can be used to predict severity and allowphysi-
cians to treat patients prior to reaching the severe or
fulminant state of infection.
In our opinion, the first class of emerging thera-
pies that will have substantial impacts on the treat-
ment of CDI is narrow-spectrum, nonabsorbable
antibiotics. As research has shown that antibiotic
treatments that cause large-scale disruption of the
microbiome are associated with increased recur-
rence and other adverse outcomes such as sepsis,
narrow-spectrum antibiotics such as fidaxomicin
and others in development (Table 2) have the poten-
tial to reducemicrobial disruptionduringCDI treat-
ment, leading tohigher sustained clinical cure, lower
recurrence rates, and reduced adverse outcomes.135
While stool products and bacterial replacements
have shown considerable promise for treating recur-
rent CDI, longitudinal and large-scale studies are
needed to examine potential long-term side effects
of altering the native bacterial community by the
addition of therapeutic bacterial communities. In
the meantime, the use of narrow-spectrum antibi-
otics and other preventative measures can reduce
recurrent cases without the necessity of bacte-
rial agents such as FMT, filtered stool, or defined
bacterial replacement. While the long-term effects
are studied, in our opinion clinicians would pre-
fer the development of pharmaceutical grade, FDA-
approved filtered stool products and therapeutics,
especially those with defined bacterial community
structures. We foresee that these types of therapies
will become a preferred alternative to FMT if they
are shown to be efficacious and safe.
Additionally, well-defined bacterial communities
with a single agent or limited taxa may be increas-
ingly used as primary prophylaxis for the preven-
tion of primary CDI.48 Through this mechanism,
the number of primary and recurrent cases of CDI
could be further reduced. While vaccines could be
another viable preventative measure, they are cur-
rently not as effective andmore clinical trials will be
needed to identify an efficacious and safe vaccine.
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An important limiting factor for clinical deploy-
ment of preventative and recurrence reduction ther-
apies is the identification of patients who are at high
risk of developing primary or recurrent CDI and
who would benefit from these therapies. To achieve
this risk stratification, large studies are starting to be
performed using medical data for the development
of predictive models for primary and recurrent CDI
risk during a patient’s treatment.136 If the risk of
primary CDI or recurrence can be accurately pre-
dicted by microbial, systemic, or intestinal/colonic
markers such as specific bacterial community com-
positions or immune cytokine levels, then the more
expensive but effective therapies, such as bezlotox-
umab, can be utilized to protect against future CDI.
This will not only increase the effective treatment
of recurrent CDI, but also lower the cost to the
healthcare system by targeting only those patients
predicted to experience primary or recurrent CDI.
We as a community are making immense strides
toward effective prevention and management of
C. difficile. The impact of these emerging therapies
will not only affect CDI but also other microbial ill-
nesses that are dependent on an interaction between
the host, native microbiota, and pathogen.
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